US20060276388A1 - Hip/pap polypeptide compositions for use in liver regeneration and for the prevention of liver failure - Google Patents
Hip/pap polypeptide compositions for use in liver regeneration and for the prevention of liver failure Download PDFInfo
- Publication number
- US20060276388A1 US20060276388A1 US10/561,034 US56103404A US2006276388A1 US 20060276388 A1 US20060276388 A1 US 20060276388A1 US 56103404 A US56103404 A US 56103404A US 2006276388 A1 US2006276388 A1 US 2006276388A1
- Authority
- US
- United States
- Prior art keywords
- amino acid
- liver
- hip
- pap
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 236
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 90
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 89
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 83
- 230000008929 regeneration Effects 0.000 title claims abstract description 82
- 238000011069 regeneration method Methods 0.000 title claims abstract description 82
- 206010019663 Hepatic failure Diseases 0.000 title claims abstract description 39
- 208000007903 liver failure Diseases 0.000 title claims abstract description 39
- 231100000835 liver failure Toxicity 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims description 33
- 230000002265 prevention Effects 0.000 title description 6
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 claims abstract description 263
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 claims abstract description 258
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 145
- 150000001413 amino acids Chemical class 0.000 claims abstract description 87
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 238000001727 in vivo Methods 0.000 claims abstract description 28
- 230000004936 stimulating effect Effects 0.000 claims abstract description 27
- 230000002297 mitogenic effect Effects 0.000 claims abstract description 24
- 238000000338 in vitro Methods 0.000 claims abstract description 19
- 208000007788 Acute Liver Failure Diseases 0.000 claims abstract description 18
- 206010000804 Acute hepatic failure Diseases 0.000 claims abstract description 15
- 231100000836 acute liver failure Toxicity 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 208000010334 End Stage Liver Disease Diseases 0.000 claims abstract description 6
- 208000011444 chronic liver failure Diseases 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 27
- 238000000034 method Methods 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 22
- 210000001185 bone marrow Anatomy 0.000 claims description 19
- 230000036961 partial effect Effects 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 238000002271 resection Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- 230000012010 growth Effects 0.000 claims description 14
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 231100000334 hepatotoxic Toxicity 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 206010019692 hepatic necrosis Diseases 0.000 claims description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 7
- 230000003082 hepatotoxic effect Effects 0.000 claims description 7
- 231100000149 liver necrosis Toxicity 0.000 claims description 7
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 6
- 102000049256 human REG3A Human genes 0.000 claims description 6
- 208000019423 liver disease Diseases 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 201000011374 Alagille syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 3
- 206010056533 Congenital hepatic fibrosis Diseases 0.000 claims description 3
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 3
- 206010063075 Cryptogenic cirrhosis Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010016202 Familial Amyloidosis Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000002125 Hemangioendothelioma Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000024571 Pick disease Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 3
- 201000005271 biliary atresia Diseases 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 201000008220 erythropoietic protoporphyria Diseases 0.000 claims description 3
- 208000003816 familial cirrhosis Diseases 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 208000007345 glycogen storage disease Diseases 0.000 claims description 3
- 208000006359 hepatoblastoma Diseases 0.000 claims description 3
- 208000014861 isolated congenital hepatic fibrosis Diseases 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 201000006038 polycystic kidney disease 4 Diseases 0.000 claims description 3
- 208000000891 primary hyperoxaluria type 1 Diseases 0.000 claims description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 201000011296 tyrosinemia Diseases 0.000 claims description 3
- 208000030954 urea cycle disease Diseases 0.000 claims description 3
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 208000012483 Crigler-Najjar syndrome type 1 Diseases 0.000 claims 1
- 101000629622 Homo sapiens Serine-pyruvate aminotransferase Proteins 0.000 claims 1
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract description 10
- 241000124008 Mammalia Species 0.000 abstract description 7
- 206010067482 No adverse event Diseases 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 66
- 238000002054 transplantation Methods 0.000 description 46
- 238000011830 transgenic mouse model Methods 0.000 description 44
- 241000699660 Mus musculus Species 0.000 description 37
- 238000012753 partial hepatectomy Methods 0.000 description 37
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 31
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 26
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 25
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 230000009261 transgenic effect Effects 0.000 description 20
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 18
- 210000005229 liver cell Anatomy 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 238000012752 Hepatectomy Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 238000011740 C57BL/6 mouse Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 101000676246 Homo sapiens 60S ribosomal protein L29 Proteins 0.000 description 12
- 101001021500 Homo sapiens Hedgehog-interacting protein Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 102000046159 human RPL29 Human genes 0.000 description 12
- 238000010348 incorporation Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 230000006820 DNA synthesis Effects 0.000 description 11
- 238000011579 SCID mouse model Methods 0.000 description 11
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 10
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 9
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 9
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 230000011278 mitosis Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 102400001368 Epidermal growth factor Human genes 0.000 description 7
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 7
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 7
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940116977 epidermal growth factor Drugs 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 229960005489 paracetamol Drugs 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000035987 intoxication Effects 0.000 description 6
- 231100000566 intoxication Toxicity 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010057110 Hepatic mass Diseases 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 101150073131 PAP gene Proteins 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- -1 alcohol Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 230000003076 paracrine Effects 0.000 description 4
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 101000966379 Bos taurus Lithostathine Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010052014 Liberase Proteins 0.000 description 2
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241000283923 Marmota monax Species 0.000 description 2
- 238000001367 Mood's median test Methods 0.000 description 2
- 101000930477 Mus musculus Albumin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101150059663 WAP gene Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010262 intracellular communication Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007433 macroscopic evaluation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101710154545 16 kDa protein Proteins 0.000 description 1
- AUYYCJSJGJYCDS-UHFFFAOYSA-N 2/3/6893 Natural products IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102100023413 GRB2-related adapter protein Human genes 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000829735 Homo sapiens GRB2-related adapter protein Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 244000185238 Lophostemon confertus Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 231100000644 Toxic injury Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- SJDACOMXKWHBOW-UHFFFAOYSA-N oxyphenisatine Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2NC1=O SJDACOMXKWHBOW-UHFFFAOYSA-N 0.000 description 1
- 229960003241 oxyphenisatine Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention concerns the use of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) for stimulating liver regeneration and also for the prevention of liver failure.
- HIP/PAP human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
- Liver failure occurs in a number of acute and chronic clinical conditions, including drug-induced hepatotoxicity, viral infections, vascular injury, autoimmune disease, or blunts trauma.
- patients subject to inborn errors of metabolism may be at risk for developing liver failure.
- Symptoms of liver failure occurring as a result of these clinical conditions include, for example, fulminant acute hepatitis, chronic hepatitis, or cirrhosis, and in many instances, the restoration of normal liver function is vital to the survival of patients.
- cirrhosis is the seventh leading cause of death and the fourth disease related cause of death in people between the ages of 25 to 44. (Source: American Liver Foundation).
- liver In acute liver disease, the liver is able to regenerate after being injured. If the disease progresses beyond the liver's capacity to regenerate new cells, the body's entire metabolism is severely affected. Loss of liver function may result in metabolic instability combined with disruption of essential bodily functions (i.e., energy supply, acid-base balance and thermoregulation.) If not rapidly reversed, complications such as uncontrolled bleeding and sepsis occur, and dependent organs such as the brain and kidneys cease to function because of toxic byproducts or because the liver is no longer synthesizing important nutrients. After large liver damage, liver tissue looses its regenerative and metabolic functions, and liver transplantation is a therapeutic strategy commonly used.
- essential bodily functions i.e., energy supply, acid-base balance and thermoregulation.
- liver transplantation is limited by the availability of human hepatocytes, liver tissue and the number of liver cells that can be transplanted safely at one time. Moreover, latence before surgery and post-surgery complications could be critical to counteract the acute phase of liver failure.
- Another therapeutic strategy consists in a liver resection (removal of a portion of the liver). The most typical indications for liver resection are a malignant tumor, a hepatocellular carcinoma or a proliferative biliary diseases including cholangiocarcinoma. Tumors can be primary (developed in the liver) or metastatic (developed in another organ, then migrated to the liver). The majority of liver metastases come from the colon.
- the single tumor or more than one tumor confined to either left or right side of the liver can be successfully resected with 5-year survival as high as 60%.
- Liver resections performed on patients with extrahepatic disease may relieve the symptoms caused by the tumor, but offer little improvement in survival.
- Benign tumors of the liver (adenoma, and focal nodular hyperplasia) can be successfully managed by liver resection as well.
- Liver resections are also performed on people willing to donate part of their liver.
- liver transplantation Taking into account the importance of liver transplantation and liver resection, Several strategies have been suggested to stimulate liver regeneration and suppress or limiting liver failure in the case of liver resection or transplantation.
- Liver cell is believed to be controlled by various growth stimulatory and growth inhibitory cytokines of autocrine or paracrine origin, however, the exact role and action mechanism of these growth factors is far from entirely understood.
- Cytokines are secreted peptides or proteins that regulate the intermediary metabolism of amino acid, proteins, carbohydrates, lipids and minerals. Cytokines include peptides or proteins that act to mediate inflammation and are involved in intracellular communication modulating cell proliferation, and adhesion of inflammatory cells to the walls of the vessels, and to the extra cellular matrix. Cytokines are essential for the communication between the liver and extrahepatic sites and within the liver itself. Cytokines interact with hormones such as glucocorticoids, resulting in a complex network of mutual control.
- cytokines exert growth activity in addition to their specific proinflammatory effects.
- the liver is an important site of cytokine synthesis and the major clearance organ for several cytokines.
- cytokines are involved in the onset of intrahepatic immune responses, in liver regeneration, and in the fibrotic and cirrhotic transformation of the liver.
- Liver cell is also believed to be controlled by various growth factors.
- Growth factors are required to regulate developmental events or required to regulate expression of genes encoding other secreted proteins that may participate in intracellular communication and coordination of development and includes, insulin-like growth factor-I and II (IGF I and II), epidermal growth factor (EGF), type a and type b transforming growth factor (TGF- ⁇ and TGF- ⁇ ), platelet-derived growth factor (PDGF).
- IGF I and II insulin-like growth factor-I and II
- EGF epidermal growth factor
- TGF- ⁇ and TGF- ⁇ type a and type b transforming growth factor
- PDGF platelet-derived growth factor
- hepatocyte growth factor HGF
- TGF ⁇ hepatocyte growth factor
- these factors may be important mediator of liver regeneration. Consequently, growth factors as TGF ⁇ , EGF or HGF with growth factor-like activities have been indicated in the treatment of liver regeneration.
- these therapeutic strategies suggested to stimulate liver regeneration and suppress liver failure, have not proved their efficacity without toxicity, and adverse effects. Namely, these growth factor favor tumor progression (Gang-Hong, et al., 1992; Lee 1992; Horiguchi, et al. 2002).
- liver transplantation is recognized as a measure for overcoming the lack of organs, and facilities for partial liver transplantation.
- partial liver transplantation cannot be considered as a safe operation for adults representing the majority of transplantation patients because the resectable liver weight of donors is often less than the necessary liver weight for recipients.
- a mean for safe and rapid liver regeneration for small grafts there is a need for a mean for safe and rapid liver regeneration for small grafts.
- an object of the present invention to provide a mean for the stimulation of liver regeneration after partial resection.
- An object of the present invention is also to provide a drug that can promote liver regeneration or hepatocyte growth after liver transplantation such as partial liver transplantation, and also after the occurrence of a discare causing liver failure, such as cirrhosis, acute hepatitis and chronic hepatitis.
- the present invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytes, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP has no adverse effects in mammals.
- a first object of the invention consists in a pharmaceutical composition for stimulating liver regeneration in vivo comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- the present invention relates to a pharmaceutical composition for stimulating liver regeneration in vivo comprising an effective amount of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- HIP/PAP human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
- FIG. 1 Schematic representation of the transgene.
- the enhancer (2 kb) and promoter (0.3 kb) of the regulatory regions of the mouse albumin gene are indicated by dotted lines.
- Exons II, III, IV, V and VI and introns of the human HIP/PAP gene are indicated by black boxes and a dotted line, respectively.
- the bovine growth hormone poly A fragment (1021-1235) pcDNA 3.1 is indicated by a dotted line.
- Plasmid DNA is indicated by the heavy line. Relevant restriction sites are indicated by the arrows.
- FIG. 2 Immunodetection of HIP/PAP protein.
- FIG. 3 Time course of in vivo hepatic regeneration after partial hepatectomy.
- FIG. 4 DNA synthesis in wild-type and HIP/PAP transgenic hepatocytes.
- FIG. 5 HIP/PAP inhibits TNF- ⁇ +ActD-induced apoptosis in cultured primary hepatocytes.
- FIG. 6 Stimulation of liver regeneration in SCID mice transplanted with hepatocytes from wild-type or HIP/PAP transgenic mice.
- FIG. 7 Stimulation of liver regeneration In SCID mice by HIP/PAP protein.
- FIG. 8 HIP/PAP protein injection stimulates liver regeneration in C57 mice.
- FIG. 9 Statistical analysis of mice population according to BrdU and mitosis.
- the distribution is statistically different between groups, which are defined according to combined median for the BrdU incorporation and mitosis 46 hours after partial hepatectomy.
- FIG. 10 Hepatic cytokines expression in the liver of transplanted mice after hepatectomy
- cytokine expression in the liver at T0 of PHX (partial hepatectomy) and after 46 hours of SCID mice transplanted with HIP/PAP versus control hepatocytes has been compared.
- Rnase protection methodology allowed to compare in the same experiment lymphotoxin- ⁇ (LT ⁇ ), TNF- ⁇ and TGF- ⁇ in a pool of 4 liver extracts HIP/PAP transgenic mice lanes a and b; SCID mice lanes c and d at T0 (lanes a and c) and at T46 hours post PHX (lanes b and d).
- Densitometric analysis quantified the signals which have been normalized versus two house keeping genes (L32 and GAPDH). mRNA levels have also been measured in liver extracts. The graph represents for each group of mice, the mean of L32 and GAPDH mRNA content.
- FIG. 11 Stat 3 activation post-hepatectomy
- FIG. 12 HIP/PAP transgenic mice are protected against acute liver failure induced by acetaminophen (APAP)
- mice Female HIP/PAP transgenic mice (Tg HIP females) and male HIP/PAP transgenic mice (Tg HIP males) treated by a lethal dose of APAP (acetaminophen) (1000 mg ⁇ kg ⁇ 1 ), has been compared to the survival of C57Bl6 control mice (CT C57Bl6 males and females), treated by APAP or PBS.
- APAP acetaminophen
- C57Bl6 control mice C57Bl6 males and females
- a significant difference in survival was observed between HIP/PAP transgenic mice injected with APAP versus C57Bl6-control mice injected with APAP.
- HIP/PAP has also a preventive effect against APAP intoxication.
- FIG. 13 HIP/PAP exhibits no toxic effects during long-term in vivo follow-up
- HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytes, in vivo, during liver failure and liver regeneration.
- HIP/PAP human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
- This protein also acts as an adhesion molecule for rat hepatocytes and interacts with extracellular matrix proteins such as laminin-1 and fibronectin.
- This protein contains a putative signal peptide, and thus belongs to group VII of the C-type lectin family, according to Drickamer's classification and structural analysis (Abergel et al., 1999).
- liver regeneration is stimulated, in vivo, in mice expressing the human HIP/PAP gene, after partial hepatectomy. Additionally, it has been found according to the invention that HIP/PAP has a mitogenic effect also in vitro in primary culture hepatocytes. In another aspect, it has also been found according to the invention that HIP/PAP has an anti-apoptotic effect against apoptosis induced by TNF- ⁇ combined with actinomycin D in primary culture hepatocytes. It has also been shown according to the invention that hepatocytes that recombinantly express HIP/PAP induce liver regeneration, when injected locally in partially liver-resected mice.
- the HIP/PAP protein when injected to mice having undergone partial hepatectomy, induces liver regeneration. Taking these observations into account, the inventors have shown that the HIP/PAP protein provides effective mitogenic and anti-apoptotic effects, and protects against liver failure, In vivo, has no adverse effects and is particularly devoid of any carcinogenic effect, in contrast to the growth factors known in the art such as HGF, TGF ⁇ or EGF, as described above.
- compositions for stimulating liver regeneration in vivo comprising an effective amount of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- HIP/PAP human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
- a first object of the invention consists in a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- the invention also concerns a pharmaceutical composition
- a pharmaceutical composition comprising a polypeptide fragment of HIP/PAP, which is effective for liver regeneration.
- This polypeptide of sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1 consists of a biologically active portion of the HIP/PAP protein, which had previously been described as a Carbohydrate Recognition Domain (CRD) sequence (Christa et al. 1994).
- CCD Carbohydrate Recognition Domain
- the pharmaceutical composition of the invention comprises a biologically active portion of HIP/PAP as described hereabove, which can be isolated from cell or tissue sources
- the biologically active portion of HIP/PAP is produced by recombinant DNA techniques, such as described in the examples.
- the biologically active portion of HIP/PAP is synthetised chemically using standard peptide synthesis techniques.
- HIP/PAP is substantially free of cellular material or other contamination proteins from the cell or tissue source from which HIP/PAP is derived, or substantially free from chemical precursors when chemically synthetised.
- the sequence are aligned for optimal comparison purposes. For example, gaps can be introduced in one or both of a first and a second amino acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes.
- Biologically active portions of HIP/PAP include peptides comprising amino acid sequences sufficiently homologous to the full length amino acid sequence of HIP/PAP of SEQ ID No. 1, which include the same number of amino acids than the full length HIP/PAP, and exhibit at least the same biological activity than HIP/PAP.
- Biologically active portions of HIP/PAP include further peptides comprising amino acid sequences sufficiently homologous to the full length amino acid sequence of HIP/PAP of SEQ ID No. 1, which include more amino acids than the full length HIP/PAP, and exhibit at least the same biological activity than HIP/PAP.
- the biologically active portion of HIP/PAP encompasses a polypeptide comprising an amino acid sequence having 90% of identity with the polypeptide of sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- a first amino acid sequence having at least 90% of identity with a second amino acid sequence comprises at least 90%, and preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of identity in amino acids with said second amino acid sequence.
- Polypeptides according to the invention comprise also variants, such as the CRD sequence from different mammals, and for example from the bovine pancreatic thread protein (BPTP) or the pancreatic associated protein 1 (PAP1) from the rat, described by Orelle, et al.
- BPTP bovine pancreatic thread protein
- PAP1 pancreatic associated protein 1
- the person skilled in the art will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID No. 11, thereby leading to changes in the amino acid sequence of HIP/PAP without altering the biological activity of HIP/PAP.
- non-essential amino acid can be made in the sequences corresponding to HIP/PAP.
- a “non essential” amino acid residue is an amino acid residue that can be altered from the wild type sequence of HIP/PAP without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity.
- a second object of the invention consists in a pharmaceutical composition for stimulating liver regeneration in vivo comprising a polypeptide of sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- Another object of the invention is a pharmaceutical composition for stimulating liver regeneration in vivo comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 27 and ending at the amino acid residue 175 of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- a further object of the invention consists in a pharmaceutical composition according to claim 1 comprising an effective amount of the polypeptide consisting of the amino acid sequence starting at the amino acid residue 27 and ending at the amino acid residue 175 of sequence SEQ ID No. 1, in combination with at least one physiologically acceptable excipient.
- Another object of the invention consists in a pharmaceutical composition for stimulating liver regeneration in vivo comprising an effective amount of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP), in combination with at least one physiologically acceptable excipient.
- HIP/PAP human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
- the inventors believe that the complete HIP/PAP protein of sequence SEQ ID No. 1, i.e. a polypeptide comprising the CRD sequence, a signal peptide, and a pro-peptide, leads to a best folding of said protein, particularly when said protein is produced through DNA recombinant techniques in eukaryotic cells that have been transfected with an expression cassette encoding it.
- a correct folding of the therapeutically active HIP/PAP may lead to a best biological efficiency for the pharmaceutical composition comprising said protein, for liver regeneration compared to a composition comprising only a portion of the protein.
- HIP/PAP has the amino acid sequence shown in SEQ ID No. 1.
- HIP/PAP is substantially identical to SEQ ID No. 1 and retains the same biological activity, for liver regeneration, when compared to the protein of sequence SEQ ID No. 1, but differs in amino acid sequence due to natural allelic variations or mutagenesis.
- HIP/PAP is a protein which comprises an amino acid sequence of at least about, 90%, and preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity with the amino acid sequence of SEQ ID No. 1.
- the invention also encompasses HIP/PAP chimeric or fusion proteins.
- a chimeric protein or a fusion protein comprises the polypeptides cited above which are fused to a non-HIP/PAP polypeptide.
- the HIP/PAP polypeptide and the non-HIP/PAP polypeptide are fused to each other.
- the non-HIP/PAP polypeptide can be fused to the N-terminus or to the C-terminus of the HIP/PAP polypeptide.
- the fusion protein is a GST-HIP/PAP fusion protein in which the HIP/PAP sequence is fused to the C-terminus of the GST sequence.
- Such fusion proteins can facilitate the purification of recombinant HIP/PAP.
- fusion proteins of the invention possess the same biological activity as HIP/PAP of SEQ ID No. 1.
- liver regeneration Two different pathways trigger liver regeneration, one causes the replication of differentiated hepatocytes or binary cells after partial hepatectomy or bile duct ligation (Fausto et al., 1994, Fausto et al., 2000).
- the second regenerative pathway is triggered after toxic injury, on massive necrosis or carcinogenesis, when the proliferation of hepatocytes or biliary cells is impaired or slowed by the injury (Factor VM et al., Petersen B et al., (1998), Akhurst B et al.). Under these conditions, it has been proposed ⁇ stem-like >> cells proliferate and differentiate into hepatocytes and biliary epithelial cells, and then repopulate the liver.
- oval cells represent a heterogeneous cellular compartment in which well-defined subpopulations have yet to be isolated.
- the oval cell compartments may participate in repopulating the liver after acute massive necrosis, and has also been identified in chronic liver diseases (Roskams T, et al., Sell S et al.).
- the phrase ⁇ liver regeneration>> concerns the process by which ⁇ stem-like >> cells proliferate and differentiate into hepatocytes and biliary epithelial cells, and then repopulate the liver as well as hepatocyte and biliary cells replication.
- Bioly active amounts concerns the amount of the composition according to the invention sufficient for treating the liver diseases associated with a decreased number of hepatocytes, in which liver regeneration conducted by HIP/PAP can restore hepatic function.
- Liver regeneration conducted by HIP/PAP can be useful in several situations such as surgery, transplantation, diseases, and after hepatoxic compounds exposure conducing to liver necrosis or partial liver necrosis.
- the pharmaceutical compositions according to the invention are suitable in the treatment of acute and chronic liver failure.
- Acute liver failure is generally caused by a massive apoptosis/necrosis of hepatocytes, and represents a devastating condition of viral or toxic origin.
- Acute liver failure is mainly induced by viral hepatitis (about 70% of cases), by drug poisoning, for example with acetaminophen during attempted suicide.
- Chronic liver failure which can be treated by the compositions according to the invention, may be induced by hepatitis B or C virus infections or by alcohol.
- NAFLD is a term recently chosen to describe a clinical and pathological syndrome that spans a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH).
- compositions according to the invention are suitable in the treatment of liver failure, consecutive to diseases such as: Hepatitis B, Hepatitis C, Urea Cycle defects, Familial hypercholesterolemia, Alcohol induced cirrhosis, Glycogen Storage Disease, Autoimmune Hepatitis, Primary Hyperoxaluria type I, Cryptogenic cirrhosis, Crigler-Najjar syndrome type I, Congenital Hepatic Fibrosis, Neimann-Pick Disease, Primary Biliary Cirrhosis, Familial Amyloidosis, Biliary Atresia, Hepatocellular Carcinoma, Primary Sclerosing Cholangitis, Hepatoblastoma, Alagille Syndrome, Hemangioendothelioma, Familial Cholestasis, Non-Carciniod neuro-endocrine, Drug induced liver failure, benign liver tumor such as focal nodular hyperplasia Liver tumors such as Hepatocellular carcinoma and Cholangiocarcinoma, A
- compositions according to the invention are suitable in the treatment of all pathological situations resulting from an exposure to hepatotoxic compounds.
- a number of hepatotoxic compounds including alcohol, virus, such as HBV, HCV or HIV, mushrooms, such as phalo ⁇ dide amanite, parasites such as Plasmodium Falciparum ) or certain therapeutics, induce cytotoxicity and liver necrosis.
- anaesthetics such as Enflurane
- neuropsychotropics such as Hydrazides
- anticonvulsants such as valproic acid
- analgesics such as Acetaminophen
- antimicrobials such as Amphotericin B or Penicillin
- hormones such as Acetohexamides
- cardiovascular drugs such as Papaverine
- Immunosuppressives and antineoplastics such as asparaginase, anti-hypertension drugs, anti-inflammatory drugs and miscellaneous drugs such as vitamin A, Oxyphenisatin, Iodide Ion.
- the pharmaceutical compositions according to the invention are suitable in the treatment of liver failure caused by acetaminophen, and have a preventive effect against acetaminophen intoxication.
- the pharmaceutical compositions according to the invention are also suitable in the treatment of liver failure, consecutive to liver resection and liver transplantation.
- the pharmaceutical composition according to the invention can be administrated to the donor of a liver transplantation, to the receipt of such transplantation, to patients after a liver resection, in order to prevent the establishment or progress of liver failure by stimulating liver regeneration.
- compositions of the invention have other beneficial effects.
- compositions according to the invention can be formulated in a galenic form suitable for the preservation of liver transplants, preferably a liquid medium wherein HIP/PAP is dissolved or suspended.
- liver failure is used herein in the broadest sense, and indicates any structural or functional injury resulting, directly or indirectly from a decreased number of liver epithelial cells i.e. hepatocytes and biliary cells.
- liver transplantation has the common meaning in the art and includes partial and whole liver transplantation in which a liver of a donor is partially or wholly resected and partially or wholly transplanted into a recipient. Partial liver transplantation is classified by operation mode into orthotopic partial liver transplantation, heterotopic partial liver transplantation, and the like, and the present invention can be applied to any of them.
- a liver transplant or a partial liver transplant from a donor corresponding to about 30-50% of the normal liver volume of a recipient is typically transplanted as a graft into the recipient whose liver has been whooly resected.
- the present invention has the effect of promoting liver regeneration or hepatocyte growth even if the graft is about 30% or less.
- Partial liver transplantation is of particular importance, regarding the significant shortage of cadaveric organ donors, associated with an exponential growth in the number of patients on waiting lists worldwide and the success of living donor liver transplantation (LDLT) in paediatric recipients.
- LDLT living donor liver transplantation
- the lack of cadaveric or size-matched liver grafts has led to the development of reduced, split, living-donor liver transplantation.
- regeneration occurs quickly in the transplanted graft, patients undergoing living donor liver grafts receive a smaller hepatic mass than those receiving a cadaveric transplant, and controversy over small-for size syndrome has escalated in recent years.
- Small-for-size liver grafts can be defined by a recognized clinical syndrome that results from the transplantation of an insufficiently large functional mass of liver in a designated recipient, and represents the greatest obstacle living donor transplantations in adults (Heaton, 2003).
- a graft to recipient body weight ratio of less than of 0.8 impairs venous inflows resulting in portal hypertension and enhanced metabolic demands in patients with in a poor clinical condition.
- the splitting of livers into right and left lobe grafts increases the potential risks of small-for-size in the recipient. These points is considered as a main factor causing small for size syndrome, which gives rise to impaired liver regeneration and necrosis of the small graft.
- liver transplant means a liver transplanted into a recipient by the transplantation operation as described above, and also includes the so-called “partial liver transplant” corresponding to a graft consisting of the part of the liver of a donor. Liver transplantation means also injection of hepatocytes (genetically modified or stimulated to proliferate or differentiate) into portal vein.
- liver regeneration means morphologic changes in which lost liver tissues are replaced by hepatocyte growth of a liver transplant or partial liver transplant, but also includes biochemical changes such as improvement, recovery, or normalisation of hepatic functions.
- Specific subjects to be treated by the composition of the invention includes, for example patients who received partial liver transplant after the liver had been wholly resected for treating hepatic failure caused by liver diseases such as hepatitis, hepatic cirrhosis of alcoholic, viral, drug or unknown cause, or hepatic cancer.
- compositions according to the invention are also suitable in the treatment of liver failure consecutive to Hepatic ischemia-reperfusion (I/R) which remains a significant limitation to both liver resection and liver transplantation, and may be responsible for liver failure, lung injury and death.
- I/R Hepatic ischemia-reperfusion
- compositions comprising the HIP/PAP protein
- therapeutic compositions comprising polypeptides fragments or biologicaly active portions of HIP/PAP.
- HIP/PAP can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby HIP/PAP is combined in admixture with a pharmaceutically acceptable carrier.
- Suitable carriers and their formulations are described in Remington's Pharmaceutical Science, 16 th ed, 1980, Mack publishing Co, edited by Oslo et al.
- ⁇ physiologically acceptable excipient is meant solid or liquid filler, diluent or substance, which may be safely used in systemic or topical administration.
- a variety of pharmaceutically acceptable carriers well known in the art include solid or liquid fillers, diluents, hydrotopes, surface active agents, and encapsulating substances.
- compositions will typically contain an effective amount of the HIP/PAP protein, for example, from on the order of about 6 ⁇ g/ml to about 10 mg/ml, together with a suitable amount of carrier to prepare pharmaceutically acceptable compositions suitable for effective administration to the patient.
- HIP/PAP may be administered parenterally or by other methods that ensure its delivery to the bloodstream in an effective form.
- HIP/PAP may preferably be administered using an intra-hepatic route.
- Dosages and desired drug concentrations of such pharmaceutical compositions may vary depending on the particular use envisioned.
- a typical effective dose in mouse experiments is about 30 ⁇ g/kg.
- Interspecies scaling of dosages can be performed in a manner known in the art., e.g. as disclosed in Mordenti et al., Pharmaceut Res 8 p1351 (1991).
- the pH of the formulation depends mainly on the particular type and the concentration of HIP/PAP protein, but preferably ranges anywhere from about 3 to about 8.
- compositions particularly well suited for the clinical administration of HIP/PAP include sterile aqueous solutions or sterile hydratable powders such as lyophilised protein.
- sterile aqueous solutions or sterile hydratable powders such as lyophilised protein.
- an appropriate amount of a pharmaceutically acceptable salt is also used in the formulation to render the formulation isotonic.
- Sterility is readily accomplished by sterile filtration through (0,2 micron) membranes.
- the HIP/PAP protein pharmaceutical composition will be formulated, dosed, and administered in a fashion consistent with good medical practice.
- Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the therapeutically ⁇ effective amount>> of HIP/PAP protein to be administered will be governed by such considerations, and is the minimum amount necessary to induce, or alternatively enhance liver regeneration and prevent liver failure. Such amount is preferably below the amount that is toxic to the mammal or renders the mammal significantly more susceptible to infections.
- ⁇ administration>> or ⁇ administered>> as used herein in reference to HIP/PAP protein refers to that administration of HIP/PAP protein which occurs prior to, simultaneous with, or after a liver resection, or a liver transplantation.
- An object of the invention is a composition comprising dividing hepatocytes in combination with a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- Another object of the invention is a composition comprising hepatocytes that have been transfected with an expression cassette that drives the expression of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- An expression cassette that drives the expression of a polypeptide as described above can be obtained for example as described in the part entitled “_Transgenic mice expressing HIP/PAP in the liver”.
- the hepatocytes as used herein are directly collected from a liver, or obtained from stem cells and particularly from bone marrow stem cells that have been differentiated into hepatocytes.
- the differentiation of bone-marrow stem cells in hepatocytes has been reported by Petersen et al., (1999) and Mitchell et al.
- the recourse to such bone-marrow stem cells can avoid recourse to hepatectomy for obtaining in vitro hepatocytes cultures.
- a further object of the invention is a composition comprising an effective amount of bone-marrow stem cells in combination with a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- the inventors believe that the administration of bone marrow stem cells treated with HIP/PAP to a patient may accelerate the liver regeneration process.
- the cellular compositions described above can be used for long-term in vitro culture of hepatocytes, for example for the purpose of in vitro cellular assays.
- the availability of the cellular compositions above avoid a recurrent recourse to hepatectomy for obtaining in vitro hepatocytes cultures.
- the invention also comprises pharmaceutical compositions for stimulating liver regeneration in vivo comprising an effective amount of a composition as defined here above.
- the polypeptide from the compositions cited above is replaced by a polypeptide fragment of HIP/PAP, a biologically active portion of HIP/PAP or the entire HIP/PAP protein as defined in the present specification.
- Another object of the invention is a process for stimulating hepatocyte growth in vitro comprising:
- Another object of the invention is a process for stimulating hepatocytes growth in vitro comprising:
- Steps (a) to (c) can be conducted according to the techniques disclosed in example 5 and to the corresponding section in the part “material and methods”.
- collecting hepatocytes means that hepatocytes are directly collected from a liver, or means that they are obtained from stem cells and particularly from bone marrow stem cells that have been differentiated into hepatocytes.
- the differentiation of bone-marrow stem cells in hepatocytes has been reported by Petersen et al., (1999) and Mitchell et al.
- the recourse to such bone-marrow stem cells can avoid recourse to hepatectomy for obtaining in vitro hepatocytes cultures.
- another object of the invention is a process for stimulating hepatocyte growth in vitro comprising:
- the inventors believe that the treatment described above enhances the bone marrow stem cells ability to regenerate the liver.
- the polypeptide from the process cited above is replaced by a polypeptide fragment of HIP/PAP, a biologically active portion of HIP/PAP or the entire HIP/PAP protein as defined in the present specification.
- Another object of the present invention consists of the use of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1 in the manufacture of a pharmaceutical composition for stimulating liver regeneration in vivo.
- a further object of the present invention consists of the use of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1 in the manufacture of a pharmaceutical composition for the prevention of the establishment or progress of liver failure in a patient at risk for developing or having been diagnosed with liver failure.
- the invention also encompasses the use of polypeptide fragments from HIP/PAP and biologically active portions of HIP/PAP as defined above.
- the liver failure is a consequence of a liver resection, a liver transplantation, or hepatitis.
- the use according to the invention concerns a patient at risk for developing or having been diagnosed with a liver failure caused by a disease comprised in the group consisting of: Hepatitis B, Hepatitis C, Urea Cycle defects, Familial hypercholesterolemia, Alcohol induced cirrhosis, Glycogen Storage Disease, Autoimmune Hepatitis, Primary Hyperoxaluria type I, Cryptogenic cirrhosis, Crigler-Najjar syndrome type I, Congenital Hepatic Fibrosis, Neimann-Pick Disease, Primary Biliary Cirrhosis, Familial Amyloidosis, Biliary Atresia, Hepatocellular Carcinoma, Primary Sclerosing Cholangitis, Hepatoblastoma, Alagille Syndrome, Hemangioendothelioma, Familial Cholestasis, Non-Carciniod neuro-endocrine, Drug induced liver failure, benign liver tumor such as focal nodular hyperplasi
- Another object of the invention is a method for stimulating liver regeneration comprising administering an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1 to a patient.
- the method according to the invention encompasses a method comprising administering an effective amount of polypeptides fragments from HIP/PAP, biologically active portions of HIP/PAP or the entire HIP/PAP protein as defined in the present specification.
- Another object of the invention is a method for the treatment of a patient with a hepatotoxic therapeutic agent effective in the prevention or treatment of a disorder or pathologic physiological conditions, comprising:
- Another object of the invention is a method for the prevention of the establishment or progress of liver failure, consequence of a liver resection, a liver transplantation, or a hepatitis comprising administering to a patient an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- the polypeptide is administrated before, during or after a liver resection or a liver transplantation.
- the polypeptide can also be administrated to the donor of a liver transplantation, or to the receipt, in order to avoid for example post-surgery complications.
- the polypeptide used is a fragment of HIP/PAP, a biologically active portion of HIP/PAP or the entire HIP/PAP protein as defined in the present specification.
- Another object of the invention is a method for stimulating liver regeneration in a patient comprising:
- Steps (a) to (d) can be conducted according to the techniques disclosed in example 5 and to the corresponding section in the part “material and methods”.
- the method comprises additional steps:
- Another object of the invention is a method for stimulating liver regeneration in a patient comprising:
- a further object of the invention is a method for stimulating liver regeneration in a patient comprising:
- Steps (a) to (d) can be conducted according to the techniques disclosed in example 5 and to the corresponding section in the part “material and methods”.
- the method comprises additional steps:
- the invention in another embodiment, relates to a method for the prevention of the establishment or progress of liver failure in a patient at risk for developing or having been diagnosed with viral or autoimmune hepatitis, or a cirrhosis comprising administering to said patient a liver failure preventative amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1.
- the polypeptide used is a fragment of HIP/PAP, a biologically active portion of HIP/PAP or the entire HIP/PAP protein as defined in the present specification.
- the invention also concerns HIP/PAP, as an active ingredient of a composition for stimulating liver regeneration in vivo, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue 36 and ending at the amino acid residue 175 of sequence SEQ ID No. 1 in combination with at least one physiologically acceptable excipient.
- HIP/PAP was produced in transgenic mouse milk carrying the rabbit WAP gene able to drive expression of the HIP/PAP gene in the mammary gland, as previously described by the inventors (Christa et al., 2000).
- Transgenic mice carrying the WAP/HIP construct were generated by microinjection into one-cell mouse zygotes of C57Bl/6xCBA hybrid strains. They were identified by tail DNA analysis on Southern blots. Mouse DNA was digested with SacI, and the generated fragments were separated on 1% agarose gels and transferred to Nytran 13N. The presence of the transgene was detected using a 4.4-kb XhoI fragment derived from the upstream region of the rabbit WAP gene.
- the resulting lactoserum (see above) was acidified to pH 4.6 by the addition of acetic acid (1 M) under stirring at 0° C. for 30 min.
- the precipitated material was removed by centrifugation at 110 000 g for 1 h in a Beckman 50.2 Ti rotor (Gagny, France).
- the supernatant was dialysed overnight at 4° C. against 1 L of 20 mM sodium acetate buffer pH 4.8, clarified by high speed centrifugation as above and filtered on a Millex 0.22 ⁇ m filter (Millipore, Guyancourt, France) before loading onto a Mono S HR 5/5 cation-exchange column previously equilibrated with 70 mM sodium acetate buffer pH 4.8.
- the flowthrough was discarded, and a 20-mL gradient of 0-500 mM NaCl in the working buffer was started when the absorbance returned to baseline.
- the column flow rate was 1 mL ⁇ min 1 and 1-mL fractions were collected.
- HIP/PAP-containing fractions were pooled, diluted in 5 vol. of 140 mM sodium acetate buffer at pH 4.0 and reapplied to the Mono S HR 5/5 column equilibrated with 140 mM sodium acetate buffer pH 4.0.
- the flowthrough was discarded and the column was developed with a 20-mL gradient ranging from 0 to 400 mM NaCl in the working buffer.
- the column flow rate was 1 mL/min and 1-mL fractions were collected. Fractions containing HIP/PAP were pooled, diluted in 1 vol. of glycerol and stored at 20° C.
- Protein concentrations in the samples were determined using the Peterson protein assay. Denaturing polyacrylamide gels in sodium dodecyl sulfate (12.5% acrylamide, SDS/PAGE) were performed according to Laemmli. Coomassie blue staining gels were scanned and quantified using an imagemaster.
- mice Expressing HIP/PAP in the Liver.
- the regulatory region of the mice albumin gene 18 was cloned upstream the HIP/PAP gene fragment to drive a human HIP/PAP gene expression specifically in the liver as described in the FIG. 1 .
- the entire NotI/KpnI-linearized construct was microinjected into single cell mouse zygotes of hybrid strains in the Experimentation on the Transgenesis department (Villejuif France).
- the 24 and 27 homozygous transgenic lines were developed from independent founders on genetic background. Animal welfare, conditions for animal handling before slaughter and all experimental procedures were ensured in line with the French Ministry of Agriculture guidelines (dated 19 th , Apr. 1988).
- mice were provided by IFFA CREDO (L'Arbresle, France) and were used as controls of HIP/PAP transgenic mice.
- SCID mice Six-week-old female severe combined immunodeficient (SCID) mice (IFFA-CREDO, L'Arbresle France) were used as the recipients of hepatocytes isolated from male HIP/PAP transgenic mice or male C57BL/6 mice (IFFA-CREDO, L'Arbresle France), to minimize any risk of cell rejection.
- SCID mice Six-week-old female severe combined immunodeficient (SCID) mice (IFFA-CREDO, L'Arbresle France) were used as the recipients of hepatocytes isolated from male HIP/PAP transgenic mice or male C57BL/6 mice (IFFA-CREDO, L'Arbresle France), to minimize any risk of cell rejection.
- Liver resection represents 70% of the total liver mass, as described by Higgins and Anderson (Higgins et al.) in two month old mice.
- Animals received one intra-peritoneal injection of 60 mg per kg body weight BrdU in 0.9% NaCl for 2 hours before dissection. They were sacrified 24, 36, 46 and 55 hours post-hepatectomy. Animals and livers were weighted and BrdU-labelled nuclei were scored after incubation with anti-BrdU antibody (clone Bu 2OA) and revelation was performed using the Universal LSAB2 horseradish peroxydase kit (Dako) with at least 20 low magnification ( ⁇ 10) microscope fields for each liver slide (Olympus BX60). More than 1600 nuclei were screened per slide.
- mice Primary mouse hepatocytes were isolated from 2 to 3 months old mice, as previously described (Klaunig et al, Renton et al) with Liberase Blendzyme. Viable hepatocytes were purified using a low speed iso-density Percoll centrifugation method, as described by (Kreamer et al). Cells were resuspended in 199 medium containing penicillin, streptomycin, fungizone, bovine serum albumin (0,1%) and fetal calf serum (10%), at densities of 2 ⁇ 10 5 and 4 ⁇ 10 5 for proliferation and apoptotic experiments respectively in Primaria plates. Cells were maintained at 37° C.
- the medium was supplemented with 3,5,3′-triiodothyronine 5 10 ⁇ 8 M, dexamethasone 10 ⁇ 7 M, Insulin 10 ⁇ g/ml 2 10 ⁇ 6 M, transferrin 5,5 ⁇ g ml, selenium 7 ng/ml, pyruvate 20 mM and foetal calf serum 5%/o.
- BrdU 20 mM
- the hepatocytes were washed with PBS, fixed, and rendered permeable in 30:70 acetic acid/ethanol solution at ⁇ 20° C. for 30 minutes.
- Incorporated BrdU was localised using the BrdU Labelling and Detection kit II.
- Replicative DNA synthesis was measured by scoring the percentage of BrdU labelled cells in at least 10 low magnification microscope field for each sample (Olympus CK2). More than 1000 hepatocytes were screened per well.
- the monolayer was fixed with 4% paraformaldehyde for 20 minutes at room temperature, stained with Hoechst 33258 (0,5 ⁇ g/ml).
- Apoptotic cells were examined at wavelengths between 350 and 460 nm using an Olympus BX60 inverted fluorescence microscope (Olympus America Inc.). Loss of cell viability was quantified using the MTT assay: 30,000 cells per well in a 96 well microtiter plate were treated with x ⁇ l (0,5 mg/ml) MTT solution, freshly dissolved in medium for 1 hour at 37° C. The medium was then aspirated and 100 ⁇ l DMSO were added to solubilize the dye.
- Hepatocytes were isolated from two-month old male HIP/PAP transgenic mice and male C57BL/6 mice, using the Liberase Blendzyme, as previously described by Klaunig and Renton. Viable hepatocytes were purified using a low-speed, iso-density Percoll centrifugation method, as described by Kreamer.
- mice Female SCID mice were anesthetized with xylazine (Bayer, Leverkusen, Germany) and ketamine (Biomérieux, Lyon France) dissolved in NaCl 0.9%, spleens were exteriorized through a small, left-flank incision, and a syringe with a 26-gauge needle was used to inject 100 ⁇ l of cell suspension (0.75 ⁇ 10 6 viable hepatocytes) in Willliams medium (Gibco/BRL). Recipient SCID was held for 30 days to allow sufficient time for the proliferation and reorganization of donor hepatocytes into the liver parenchyma, before partial hepatectomy was performed.
- HIP/PAP protein was produced and purified as previously described (Christa et al., 2000), and was diluted in NaCl 0.9%. at 6 ⁇ g/ml. 100 ⁇ l HIP/PAP protein or PBS (Phosphate Buffered Saline) was injected into the spleens of Severe Cellular ImmunoDeficient (SCID) mice 36 h after partial hepatectomy. The animals were killed 8 days after partial hepatectomy.
- RNA from frozen liver tissues was extracted according to TRIZOL reagent (Life Technologies) supplied instructions.
- CDNA was synthesised by 200 units Moloney murine leukaemia reverse transcriptase (Promega) and primed with 400 ng random primers (Invitrogen), from 1 ⁇ g total RNA, at 42° C. for 45 min, in the presence of 10 U RNasin, 1 ⁇ buffer supplied by the enzyme, 40 mmol l ⁇ 1 of the four deoxynucleotides.
- PCR was performed with 40 amplification cycles of 1 min each at the following temperatures: 94° C., 60° C., and 72° C., from 1 ⁇ 8 cDNA, by using pure TaqTM Ready-To-GoTM PCR Beads (Amersham Biosciences).
- Human HIP/PAP transgene expression was detected with primers 19/101.
- Endogenous HIP/PAP/Mo gene expression was detected with 104/105 primers which from the mouse published sequence of Itoh and Terakoa ( ).
- HIP/PAP Assays Western Blot Analysis, Immunohistochemistry and ELISA TEST.
- HIP/PAP protein was produced and purified from the milk of lactating transgenic mice as described above, and according to Christa et al., 2000. Western blot analysis and immunohistochemistry were performed with pre-HIP antibodies, as previously described (Christa et al., 1999). Serum HIP/PAP levels were assayed using a sandwich ELISA test, in accordance with the manufacturer's instructions (Dynabio, La Gaude, France).
- Activation of the transcription factor STAT3 was studied by the TramsAM kit (Active motif) and by Western blot analysis performed as previously described (Simon et al., 2003), with total anti-STAT3 and anti-phospho STAT3 antibodies (Santa Cruz)
- Liver cytokines expression were evaluated by RNase protection assay as previously described (Tralhao J G, 2002)
- results for hepatocytes in primary culture were expressed as mean+/ ⁇ SD, and statistical signifiance (P ⁇ 0.05) was determined using an unpaired Student's test.
- results for hepatocytes in primary culture were expressed as mean+/ ⁇ SD, and statistical signifiance (P ⁇ 0.05) was determined using an unpaired Student's test.
- In Vivo liver regeneration was represented by the percentages of nuclei incorporating BrdU using the box and whiskers representation, and the statistical signifiance of differences between HIP/PAP transgenic and wild-type mice was determined by the Mann-Whitney U-test (P ⁇ 0.05), because the data distribution was not normal (Statview 5′, Abacus Concepts, Berkeley, Calif.).
- HIP/PAP transgene was specifically expressed in the liver, and HIP/PAP-expressing mice did not develop livers tumours, after a two year following.
- Immunohistolocalization analysis detected HIP/PAP protein in the liver of transgenic mice as diffuse intra-hepatocyte immunostaining, occupying most of the cytoplasm of the hepatocytes ( FIGS. 2A, 1 and 2 ). Staining was heterogenous and positive regions were located either in centrolobular or portal areas of the liver acinus. This heterogeneous distribution likely reflects HIP/PAP secretion, thus hepatocytes could be either positive or negative before or after HIP/PAP secretion respectively.
- HIP/PAP protein was secreted into the serum (250 ng/ml to 700 ng/ml) in homozygote transgenic lines 24 and 27, and into the culture medium of primary hepatocytes (30 to 120 ng/ml per 2.10 5 cells). No difference in morphology and plo ⁇ dy was detected between HIP/PAP-expressing and control hepatocytes by histological examination (mouse hepatocytes were 80% binuclear after adhesion as previously described by Leist et al.). HIP/PAP immunohistochemistry views of hepatocytes in culture showed that more than 50% of the hepatocytes were HIP/PAP labelled ( FIGS. 2A, 3 and 4 ).
- HIP/PAP Western-blot analysis detected HIP/PAP as a 16 kDa protein in liver extracts and primary culture hepatocytes from HIP/PAP transgenic mice ( FIG. 2B ). HIP/PAP protein was not detected in wild type mice. Actin hybridization allowed an accurate estimation of the 50 ⁇ g protein loaded for livers and hepatocytes (50 ⁇ g corresponded approximately to 50,000 hepatocytes).
- FIG. 3A Low magnification ( ⁇ 20) views for times 24, 36, 46 and 55 hours post partial hepatectomy are presented FIG. 3A .
- percentages of positive BrdU cells were higher in HIP/PAP transgenic than in wild-type livers, despite the low overall frequency of nuclei which had incorporated BrdU in both groups.
- HIP/PAP protein may act as Growth Factor during liver regeneration
- liver recovery was higher in the HIP/PAP transgenic than in wild-type mice, and the difference was statistically significant at 48 hours (p ⁇ 0.001), 60 hours (p ⁇ 0.003) and 96 hours (p ⁇ 0.002). At 120 hours, the liver weight recovered to the same percentage in both wild-type and HIP/PAP transgenic mice.
- HIP/PAP is a secreted protein, and it was therefore tested whether it might act as a paracrine mitogenic factor.
- HIP/PAP protein 40 ng ⁇ ml ⁇ 1
- Rat hepatocytes in primary cultures were not sensitive to cell death caused by TNF- ⁇ treatment alone. Instead, they die through apoptosis after exposure to TNF- ⁇ combined with a low dose of ActD (22).
- Mouse hepatocyte cell death was induced by TNF- ⁇ combined with an ActD dose as low as 0.05 ⁇ g/ml, despite ActD (0.05 ⁇ g ml ⁇ 1 ) alone did not induce any loss of viability ( FIG. 5B ). It is shown ( FIG.
- hepatocytes expressing HIP/PAP resisted TNF- ⁇ +ActD-induced apoptosis after a 16-17 hours of treatment.
- Cell survival reached 75% versus 43% (p ⁇ 0.0001) for 2 ng ml ⁇ 1 TNF- ⁇ , and 60% versus 27% for 20 ng ml ⁇ 1 TNF- ⁇ , (p ⁇ 0.0001).
- the LD 50 for TNF- ⁇ was over 40 ng ml ⁇ 1 and 1 ng ml ⁇ 1 in HIP/PAP and wild-type hepatocytes, respectively.
- liver regeneration was tested in the SCID recipient mice.
- mice injected with HIP/PAP represented a group statistically different from mice injected with NaCl.
- Table I TABLE I BrDU positive nuclei (%) Mitotic hepatocytes (%) NaCl HIP combined NaCl HIP combined n 16 15 31 16 15 31 mean 12.669 22.313 17.335 0.525 1.567 1.029 median 7.300 23.000 15.800 0.000 0.7200 0.000 P-value 0.0038 0.0113
- mice in four nominal groups according to the combined median for BrdU and mitosis have been used to classify the mice in four nominal groups according to the combined median for BrdU and mitosis.
- Liver regeneration has to be primed by TNF- ⁇ and IL-6 cytokines in order to initiate the hepatocytes to enter the G1 phase of the cell cycle.
- the STAT3 transcription factor is phosphorylated-activated and translocated to the nucleus.
- the persistence of TNF-a/IL6 expression and STAT3 activation is deleterious and delays the time-course of regeneration.
- the effect of HIP/PAP on liver cytokine expression and on the activation of STAT3 has been investigated.
- cytokine expression in the liver at T0 of PHX (partial hepatectomy) and after 46 hours of SCID mice transplanted with HIP/PAP versus control hepatocytes has been compared.
- lymphotoxin- ⁇ (LT ⁇ ) , TNF- ⁇ and TGF- ⁇ in a pool of 4 liver extracts FIG. 10 ; HIP/PAP transgenic mice lanes a and b; SCID mice lanes c and d) at T0 (lanes a and c) and at T46 hours post PHX (lanes b and d).
- Densitometric analysis quantified the signals which have been normalized versus two house keeping genes (L32 and GAPDH). The results showed no difference in the hepatic expression of TGF- ⁇ when transplantation was done with HIP/PAP or control hepatocytes: at 46 hours post PHX, TGF- ⁇ increased at the same extent.
- HIP/PAP is a Protective Drug against APAP-Induced Acute Liver Failure
- APAP acetaminophen
- NAPQ1 a highly reactive metabolite that depletes the intracellular pool of GSH, a non-protein thiol with both oxidant scavenger and redox regulating capacities. Consequently, during APAP intoxication in the mouse, toxic reactive oxygen species (ROS) are generated leading to acute liver failure.
- ROS reactive oxygen species
- HIP/PAP protein in a mouse model of APAP-induced acute liver failure has been investigated.
- Drug-induced acute liver failure was achieved in 24 HIP/PAP transgenic and 24 C57/bl6 mice (12 males and 12 females in each group) by the intraperitoneal injection of a lethal dose of 1000 mg/ml (APAP 1000 ) diluted in 200 ⁇ L sterile phosphate buffer saline.
- HIP/PAP protein is a good candidate for clinical therapeutic applications aimed at preventing and treating liver failure, through its action on both the regenerative and live status of liver cells ( FIG. 12 ).
- HIP/PAP protein has been injected by intravenous in the tail of C57Bl6 1 hour before APAP.
- the results showed a dose dependent preventive protection of HIP/PAP protein: for 600 ng, 4/10 and 2/10 HIP/PAP-injected and saline-injected mice survived respectively; for 1200 ng, 8/10 and 2/10 HIP/PAP-injected and saline-injected mice survived, respectively.
- Any drug capable of stimulating liver cell proliferation has a potential to induce cancer, so that the risks of developing HCC must be determined prior to any administration.
- Two models of transgenic mice expressing human HIP/PAP gene under either the promoter of the mouse albumin gene (two strains) or the promoter of the mouse metallothioneine gene (two strains) have been developed. Both models target HIP/PAP gene expression in the liver and secretion of the HIP/PAP protein in the blood. None of the HIP/PAP-expressing mice had developed liver (or other) tumours, after a two-year follow-up period.
- HIP/PAP protein The effects of HIP/PAP protein on a model of liver carcinogenesis from the long-term follow-up of bi-transgenic mice has been investigated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/032,521 US8329661B2 (en) | 2003-06-18 | 2011-02-22 | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03291487A EP1488798A1 (en) | 2003-06-18 | 2003-06-18 | HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure |
EP032914871 | 2003-06-18 | ||
PCT/EP2004/006633 WO2004112824A1 (en) | 2003-06-18 | 2004-06-18 | Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/006633 A-371-Of-International WO2004112824A1 (en) | 2003-06-18 | 2004-06-18 | Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/032,521 Division US8329661B2 (en) | 2003-06-18 | 2011-02-22 | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060276388A1 true US20060276388A1 (en) | 2006-12-07 |
Family
ID=33396036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,034 Abandoned US20060276388A1 (en) | 2003-06-18 | 2004-06-18 | Hip/pap polypeptide compositions for use in liver regeneration and for the prevention of liver failure |
US13/032,521 Expired - Lifetime US8329661B2 (en) | 2003-06-18 | 2011-02-22 | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/032,521 Expired - Lifetime US8329661B2 (en) | 2003-06-18 | 2011-02-22 | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060276388A1 (da) |
EP (2) | EP1488798A1 (da) |
JP (1) | JP4709141B2 (da) |
CN (1) | CN1835764B (da) |
AT (1) | ATE480254T1 (da) |
AU (1) | AU2004248914B2 (da) |
CA (1) | CA2529896C (da) |
CY (1) | CY1110941T1 (da) |
DE (1) | DE602004029038D1 (da) |
DK (1) | DK1638594T3 (da) |
ES (1) | ES2351893T3 (da) |
PL (1) | PL1638594T3 (da) |
PT (1) | PT1638594E (da) |
SI (1) | SI1638594T1 (da) |
WO (1) | WO2004112824A1 (da) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011003098A1 (en) * | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US9212212B2 (en) | 2006-06-21 | 2015-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Targeting complement factor H for treatment of diseases |
US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
US9650447B2 (en) | 2010-05-14 | 2017-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Complement receptor 2 (CR2) targeting groups |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
CN113307845A (zh) * | 2018-09-18 | 2021-08-27 | 广州领晟医疗科技有限公司 | 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途 |
US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
US11567080B2 (en) * | 2016-01-08 | 2023-01-31 | Kyoto University | Diagnostic agent and medicine comprising ADAMTS13 as main ingredient |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1488798A1 (en) * | 2003-06-18 | 2004-12-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure |
EP1900749A1 (en) | 2006-09-12 | 2008-03-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells |
US7923014B2 (en) * | 2007-02-12 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Expression and purification of HIP/PAP and uses therefor |
EP2260857A1 (en) * | 2009-06-11 | 2010-12-15 | Alfact Innovation | Novel applications of HIP/PAP or derivatives thereof |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
EP2687225A1 (en) | 2012-07-19 | 2014-01-22 | Alfact Innovation | HIP/PAP protein and derivatives thereof for use in treating cancer |
US8893292B2 (en) | 2012-11-14 | 2014-11-18 | Mitsubishi Electric Research Laboratories, Inc. | Privacy preserving statistical analysis for distributed databases |
WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
FR3004354A1 (fr) | 2013-04-10 | 2014-10-17 | Alfact Innovation | Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline |
RU2559935C1 (ru) * | 2014-06-10 | 2015-08-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ стимуляции регенерации резецированной печени l-аргинином |
RU2590859C1 (ru) * | 2015-06-30 | 2016-07-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Способ дистантной стимуляции регенерации гепатоцитов |
RU2601160C1 (ru) * | 2015-07-09 | 2016-10-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМУ Минздрава России) | Способ резекции печени у мелких лабораторных животных |
RU2636194C1 (ru) * | 2016-11-23 | 2017-11-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ стимуляции репаративной регенерации печени после ее резекции |
CN107936111B (zh) * | 2017-12-16 | 2021-09-07 | 广州安辰新药研究院有限公司 | 一种hip/pap蛋白的制备方法 |
CN110627866B (zh) * | 2019-10-23 | 2022-10-18 | 广州领晟医疗科技有限公司 | 多肽rly4及其促进肝再生和抑制肝细胞凋亡的用途 |
CN110669126B (zh) * | 2019-10-23 | 2022-08-16 | 广州领晟医疗科技有限公司 | 多肽gpr5及其促进肝细胞增殖和抑制肝细胞凋亡的用途 |
CN117015386A (zh) * | 2020-12-21 | 2023-11-07 | 旗舰创业创新五公司 | 细胞周转因子用于增加组织再生的用途 |
EP4085922A1 (en) | 2021-05-07 | 2022-11-09 | The Healthy Aging Company | Hip/pap protein or a derivative thereof for treating peripheral neuropathy |
CN113528639B (zh) * | 2021-06-04 | 2023-06-13 | 南方医科大学南方医院 | 一组预测慢加急性肝功能衰竭预后的标志物及其应用 |
EP4252766A1 (en) | 2022-04-01 | 2023-10-04 | The Healthy Aging Company | Hip/pap protein or a derivative thereof for treating and/or preventing a disorder characterized by a high cxcl5 serum level in an individual |
WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
CN116004825A (zh) * | 2022-12-08 | 2023-04-25 | 上海交通大学医学院附属上海儿童医学中心 | Reg3a在制备辅助诊断或治疗肝母细胞瘤的试剂或药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2661187B1 (fr) * | 1990-04-20 | 1994-08-05 | Inst Nat Sante Rech Med | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. |
FR2700011B1 (fr) * | 1992-12-24 | 1995-02-24 | Inst Nat Sante Rech Med | Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP. |
EP1488798A1 (en) * | 2003-06-18 | 2004-12-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure |
-
2003
- 2003-06-18 EP EP03291487A patent/EP1488798A1/en not_active Withdrawn
-
2004
- 2004-06-18 CN CN200480023661.0A patent/CN1835764B/zh not_active Expired - Lifetime
- 2004-06-18 SI SI200431542T patent/SI1638594T1/sl unknown
- 2004-06-18 DE DE602004029038T patent/DE602004029038D1/de not_active Expired - Lifetime
- 2004-06-18 PT PT04740077T patent/PT1638594E/pt unknown
- 2004-06-18 AU AU2004248914A patent/AU2004248914B2/en not_active Ceased
- 2004-06-18 CA CA2529896A patent/CA2529896C/en not_active Expired - Fee Related
- 2004-06-18 EP EP04740077A patent/EP1638594B1/en not_active Expired - Lifetime
- 2004-06-18 AT AT04740077T patent/ATE480254T1/de active
- 2004-06-18 JP JP2006516001A patent/JP4709141B2/ja not_active Expired - Lifetime
- 2004-06-18 WO PCT/EP2004/006633 patent/WO2004112824A1/en active Application Filing
- 2004-06-18 DK DK04740077.5T patent/DK1638594T3/da active
- 2004-06-18 ES ES04740077T patent/ES2351893T3/es not_active Expired - Lifetime
- 2004-06-18 PL PL04740077T patent/PL1638594T3/pl unknown
- 2004-06-18 US US10/561,034 patent/US20060276388A1/en not_active Abandoned
-
2010
- 2010-11-24 CY CY20101101060T patent/CY1110941T1/el unknown
-
2011
- 2011-02-22 US US13/032,521 patent/US8329661B2/en not_active Expired - Lifetime
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9212212B2 (en) | 2006-06-21 | 2015-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Targeting complement factor H for treatment of diseases |
WO2011003098A1 (en) * | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
US9650447B2 (en) | 2010-05-14 | 2017-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Complement receptor 2 (CR2) targeting groups |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
US11567080B2 (en) * | 2016-01-08 | 2023-01-31 | Kyoto University | Diagnostic agent and medicine comprising ADAMTS13 as main ingredient |
CN113307845A (zh) * | 2018-09-18 | 2021-08-27 | 广州领晟医疗科技有限公司 | 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CA2529896A1 (en) | 2004-12-29 |
CY1110941T1 (el) | 2015-06-10 |
WO2004112824A1 (en) | 2004-12-29 |
PL1638594T3 (pl) | 2011-08-31 |
DE602004029038D1 (de) | 2010-10-21 |
SI1638594T1 (sl) | 2011-03-31 |
EP1638594A1 (en) | 2006-03-29 |
US20110144036A1 (en) | 2011-06-16 |
JP2006527733A (ja) | 2006-12-07 |
ES2351893T3 (es) | 2011-02-11 |
DK1638594T3 (da) | 2010-12-20 |
CA2529896C (en) | 2014-02-11 |
EP1488798A1 (en) | 2004-12-22 |
JP4709141B2 (ja) | 2011-06-22 |
PT1638594E (pt) | 2010-12-03 |
CN1835764A (zh) | 2006-09-20 |
CN1835764B (zh) | 2014-07-09 |
AU2004248914B2 (en) | 2010-02-25 |
AU2004248914A1 (en) | 2004-12-29 |
EP1638594B1 (en) | 2010-09-08 |
ATE480254T1 (de) | 2010-09-15 |
US8329661B2 (en) | 2012-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8329661B2 (en) | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure | |
KR20050096212A (ko) | 당뇨병 치료제 | |
KR101486114B1 (ko) | Milk fat globule ― EGF factor 8(MFGE8)을 이용한 간 재생 및 간 질환 개선 용도 | |
Sreedhar et al. | Depletion of cardiac 14-3-3η protein adversely influences pathologic cardiac remodeling during myocardial infarction after coronary artery ligation in mice | |
Shiota et al. | Hepatocyte growth factor in transgenic mice | |
EP1529533A1 (en) | Use of GH secretagogues in hypoxic-ischemic brain injury | |
US6436393B1 (en) | Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof | |
US20240101624A1 (en) | Brown fat-selective adipokines | |
JP2000515137A (ja) | 軸索の成長を制御する方法 | |
Kitagawa et al. | Induction of DNA fragmentation and HSP72 immunoreactivity by adenovirus‐mediated gene transfer in normal gerbil hippocampus and ventricle | |
Musaro et al. | Attenuating muscle wasting: cell and gene therapy approaches | |
Stem | Articles in PresS. Am J Physiol Renal Physiol (October 13, 2010). doi: 10.1152/ajprenal. 00073.2010 | |
Wideman | Manipulating proglucagon processing in the pancreatic alpha-cell for the treatment of diabetes | |
Kelly et al. | Intravenous cell therapy for acute renal failure with serum amyloid A protein | |
AU2008202259A1 (en) | Treatment for diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITE RENE DESCARTES, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHRISTA, LAURENCE;BRECHOT, CHRISTIAN;SIMON-GAGE-SOUFFLOT, MARIE-THERESE;AND OTHERS;REEL/FRAME:017981/0684;SIGNING DATES FROM 20060504 TO 20060605 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHRISTA, LAURENCE;BRECHOT, CHRISTIAN;SIMON-GAGE-SOUFFLOT, MARIE-THERESE;AND OTHERS;REEL/FRAME:017981/0684;SIGNING DATES FROM 20060504 TO 20060605 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |